Staphylococcus aureus is bacteria usually found on nose or skin of healthy people. Methicillin-resistant staphylococcus aureus (MRSA) is a type of staphylococcus aureus which is resistant to methicillin, a beta-lactam antibiotic. The MRSA strains do not give response to methicillin treatment. Around nearly 1% of the population having staphylococcus aureus on their nose or skin are diseased by MRSA. The infection sources skin & tissue infection and is spread through skin to skin contact. With increasing prevalence of the development of antibiotic resistant strains among all age groups, growing awareness, and investment by key players in the R&D of MRSA drugs, the methicillin-resistant staphylococcus aureus (MRSA) drugs market is likely to register high growth during the forecasted period.
Increasing occurrence of the development of antibiotic resistant strains among all age groups, increasing awareness about MRSA, and rising market penetration of emerging players, are the factors driving the growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market. However, growth of treatment-emergent resistance in MRSA-infected patients may hinder the growth of the market. Moreover, ongoing R&D, and emerging markets might provide with several growth opportunities in the forecasted year.
The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market is segmented on the basis of drug class, route of administration, and distribution channel, and geography. The market is segmented by drug class as oxazolidinone, lipopeptide, cephalosporin, tetracycline, folate antagonists, lipoglycopeptide, and other drug classes. Further, the market is segmented by route of administration as oral and parenteral. Distribution channel comprises retail pharmacy, hospital pharmacy, and online pharmacy.
Based on geography, global methicillin-resistant staphylococcus aureus (MRSA) drugs market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is further bifurcated into U.S., Canada, and Mexico whereas Europe segment consist of UK, Russia, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific while RoW is bifurcated into South America, Middle East, and Africa.
The key market players include The Medicines Company, Basilea Pharmaceutica Ltd., Theravance Biopharma, Allergan plc., 3M, Pfizer, Inc., and Merck & Co., Inc., among others.
The key takeaways from the report
The report will provide detailed analysis of Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market with respect to major segments such as drug class, route of administration, and distribution channel
The report will include the qualitative and quantitative analysis with market estimation over 2016 – 2025 and compound annual growth rate (CAGR) between 2017 and 2025
Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
An exhaustive regional analysis of Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market has been included in the report
Profile of the key players in the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market
Drug Class Segments
Other Drug Classes
Route of Administration Segments
Distribution Channel Segments
Rest of Europe
Rest of Asia-Pacific
Market Research Outlet